LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
LENZ Therapeutics (Nasdaq: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, has scheduled its third quarter 2024 financial results and business update webcast for November 6, 2024, at 8:00 a.m. EST. The company will host a conference call accessible via phone and webcast, with a replay available on their website for 30 days following the event.
LENZ Therapeutics (Nasdaq: LENZ), un'azienda biofarmaceutica in fase pre-commerciale che sviluppa colliri a base di aceclidina per la presbiopia, ha programmato il suo risultato finanziario del terzo trimestre 2024 e l'aggiornamento aziendale in streaming per il 6 novembre 2024, alle 8:00 a.m. EST. L'azienda ospiterà una conference call accessibile tramite telefono e webcast, con una registrazione disponibile sul loro sito web per 30 giorni dopo l'evento.
LENZ Therapeutics (Nasdaq: LENZ), una empresa biofarmacéutica en etapa precomercial que desarrolla gotas para los ojos a base de aceclidina para la presbicia, ha programado su informe financiero del tercer trimestre de 2024 y actualización comercial en un webcast para el 6 de noviembre de 2024, a las 8:00 a.m. EST. La empresa llevará a cabo una conferencia telefónica accesible por teléfono y webcast, con una repetición disponible en su sitio web durante 30 días después del evento.
LENZ Therapeutics (Nasdaq: LENZ)는 노안 치료를 위한 에세클리딘 기반 점안제를 개발하는 상장 전 단계의 생명공학 회사로, 2024년 3분기 재무 결과 및 비즈니스 업데이트 웹캐스트를 2024년 11월 6일 오전 8시 EST로 예정했습니다. 회사는 전화 및 웹캐스트를 통해 접근 가능한 컨퍼런스 콜을 주최할 예정이며, 이벤트 종료 후 30일 동안 자사 웹사이트에서 재방송을 시청할 수 있습니다.
LENZ Therapeutics (Nasdaq: LENZ), une entreprise biopharmaceutique en phase pré-commerciale développant des gouttes oculaires à base d'aceclidine pour la presbytie, a programmé son résultat financier du troisième trimestre 2024 et une mise à jour commerciale en webcast pour le 6 novembre 2024, à 8h00 EST. L'entreprise organisera un appel conférence accessible par téléphone et en webcast, avec un replay disponible sur leur site web pendant 30 jours après l'événement.
LENZ Therapeutics (Nasdaq: LENZ), ein biopharmazeutisches Unternehmen in der prä-kommerziellen Phase, das augentropfen auf Basis von Aceclidin zur Behandlung von Presbyopie entwickelt, hat sein Finanzergebnis des dritten Quartals 2024 und ein Unternehmensupdate-Webcast für den 6. November 2024 um 8:00 Uhr EST angesetzt. Das Unternehmen wird eine Telefonkonferenz veranstalten, die sowohl telefonisch als auch im Webcast zugänglich ist, mit einer Wiederholung, die 30 Tage nach der Veranstaltung auf ihrer Website verfügbar sein wird.
- None.
- None.
SAN DIEGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, November 6, 2024 at 8:00 a.m. EST to report its third quarter 2024 financial results and provide a business update.
To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 7959303. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
When will LENZ Therapeutics (LENZ) report Q3 2024 earnings?
How can I access LENZ Therapeutics (LENZ) Q3 2024 earnings call?
What is LENZ Therapeutics' (LENZ) main product in development?
